Cairns T, Lee J, Goldberg L, Cook T, Simpson P, Spackman D, Palmer A, Taube D
Renal Unit, St. Mary's Hospital, London, United Kingdom.
Transplantation. 1995 Dec 15;60(11):1202-7.
Natural anti-carbohydrate antibodies are central to hyperacute rejection in ABO-incompatible allotransplantation and in discordant xenotransplantation. ABO-incompatible rejection has been inhibited successfully using intravenous soluble carbohydrates as antibody inhibitors. The approach has been less successful previously in pig to primate xenotransplantation, where the necessary concentrations of a partial inhibitor (Gal alpha 1-6Glc) proved highly toxic. In this study, we have identified more effective inhibitors of the dominant human anti-pig antibodies that bind to the pentasaccharide Gal alpha 1-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4Glc beta 1-. The inhibitors are the terminal disaccharide (Gal alpha 1-3Gal) and terminal trisaccharide (Gal alpha 1-3Gal beta 1-4GlcNAc) of the target pentasaccharide. Twelve sera (3 from each ABO blood group) were tested in 3 different assays: lymphocytotoxic, lymphocyte flow cytometry, and solid-phase antigen ELISA. Fifty percent to 75% inhibition of human IgG and IgM was achieved using the disaccharide and trisaccharide inhibitors in the range of 10-50 mM. Disaccharide (70 mM) was used to inhibit hyperacute thrombosis in pig kidneys perfused for 40 min with heparinized human AB whole blood. The disaccharide completely inhibited red cell occlusion of glomerular but not of intertubular capillaries, although there was residual platelet thrombus in glomeruli. Disaccharide and trisaccharide can, therefore, be used in concentrations shown for other carbohydrate inhibitors to be nontoxic, for inhibition of hyperacute pig-to-human xenograft rejection. The inhibition is incomplete, however, and other antigen specificities and other rejection mechanisms are likely to be involved.
天然抗碳水化合物抗体在ABO血型不相容的同种异体移植和非协调性异种移植的超急性排斥反应中起核心作用。使用静脉注射可溶性碳水化合物作为抗体抑制剂已成功抑制了ABO血型不相容的排斥反应。该方法此前在猪到灵长类动物的异种移植中不太成功,在这种移植中,部分抑制剂(Galα1-6Glc)所需的浓度被证明具有高毒性。在本研究中,我们鉴定出了更有效的抑制剂,可抑制与五糖Galα1-3Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ1-结合的主要人类抗猪抗体。这些抑制剂是目标五糖的末端二糖(Galα1-3Gal)和末端三糖(Galα1-3Galβ1-4GlcNAc)。在三种不同的检测中对12份血清(每个ABO血型组3份)进行了检测:淋巴细胞毒性检测、淋巴细胞流式细胞术检测和固相抗原ELISA检测。使用10-50 mM范围内的二糖和三糖抑制剂可实现对人IgG和IgM 50%至75%的抑制。使用二糖(70 mM)抑制用肝素化人AB全血灌注40分钟的猪肾中的超急性血栓形成。二糖完全抑制了肾小球的红细胞阻塞,但未抑制肾小管间毛细血管的红细胞阻塞,尽管肾小球中仍有残留的血小板血栓。因此,二糖和三糖可用于其他碳水化合物抑制剂显示无毒的浓度,以抑制猪到人的超急性异种移植排斥反应。然而,这种抑制并不完全,可能还涉及其他抗原特异性和其他排斥机制。